GLUE Monte Rosa Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GLUE matters now
Monte Rosa Therapeutics, Inc. (GLUE) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.04 with -6.04% on the session and $1.50B in market capitalization; recent performance reads 1-month +4.15% and YTD +16.77%.
The latest financial table shown here is Q1 2026, with revenue of $4.2M, net income of $-44.5M, and EPS of $-0.68. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.6%.
The latest indexable market news headline is "Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $37.00; recent insider activity includes Townson Sharon filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.30
P/S
27.76
EV/EBITDA
-8.67
DCF Value
$24.75
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.3%
Operating Margin
-345.2%
Net Margin
-302.7%
ROE
-41.0%
ROA
-17.7%
ROIC
-21.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.2M | $-44.5M | $-0.68 |
| Q4 2025 | $2.8M | $-46.1M | $-0.70 |
| FY 2025 | $123.7M | $-38.6M | $-0.46 |
| Q3 2025 | $12.8M | $-27.1M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.00
Target (Median)
$37.00
Target Range
$31.00 - $37.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.60
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.